Omega Therapeutics, Inc. financial data

Symbol
OMGA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
140 First Street, Suite 501, Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 346 % -62.5%
Debt-to-equity 208 % +643%
Return On Equity -136 % -64%
Return On Assets -44.2 % +31.8%
Operating Margin -3.24K % +34.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 55.2M shares +0.24%
Common Stock, Shares, Outstanding 55.2M shares +0.24%
Entity Public Float 140M USD +75.3%
Common Stock, Value, Issued 55K USD 0%
Weighted Average Number of Shares Outstanding, Basic 55.2M shares +8.93%
Weighted Average Number of Shares Outstanding, Diluted 55.2M shares +8.93%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.36M USD +357%
Research and Development Expense 72.5M USD -16.7%
General and Administrative Expense 27.3M USD +11.5%
Operating Income (Loss) -94.9M USD +12.6%
Nonoperating Income (Expense) 2.62M USD +223%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -92.3M USD +14.4%
Earnings Per Share, Basic -1.66 USD/shares +25.2%
Earnings Per Share, Diluted -1.66 USD/shares +25.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 60M USD -42.6%
Marketable Securities, Current 4.99M USD -90.8%
Assets, Current 70.9M USD -52.4%
Property, Plant and Equipment, Net 5.01M USD +19.1%
Operating Lease, Right-of-Use Asset 107M USD +3830%
Other Assets, Noncurrent 74K USD -59.3%
Assets 184M USD +17.5%
Accounts Payable, Current 1.58M USD -57.1%
Employee-related Liabilities, Current 1.69M USD +15.7%
Accrued Liabilities, Current 4.49M USD -34.5%
Liabilities, Current 24.7M USD +36.3%
Operating Lease, Liability, Noncurrent 97.7M USD +12776%
Other Liabilities, Noncurrent 6.02M USD +1671%
Liabilities 142M USD +327%
Accumulated Other Comprehensive Income (Loss), Net of Tax -14K USD +97.1%
Retained Earnings (Accumulated Deficit) -355M USD -35.2%
Stockholders' Equity Attributable to Parent 41.4M USD -66.4%
Liabilities and Equity 184M USD +17.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11.8M USD +58%
Net Cash Provided by (Used in) Financing Activities -1.07M USD -103%
Net Cash Provided by (Used in) Investing Activities 4.47M USD -79.8%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 55.2M shares +0.24%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -8.41M USD -125%
Interest Paid, Excluding Capitalized Interest, Operating Activities 484K USD +25.1%
Deferred Tax Assets, Valuation Allowance 105M USD +41.4%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 134M USD +78.7%
Operating Lease, Liability 110M USD +4681%
Depreciation 1.64M USD +5.2%
Payments to Acquire Property, Plant, and Equipment 535K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -92.1M USD +14.1%
Lessee, Operating Lease, Liability, to be Paid 199M USD +8223%
Property, Plant and Equipment, Gross 11.5M USD +15.3%
Operating Lease, Liability, Current 12M USD +681%
Lessee, Operating Lease, Liability, to be Paid, Year Two 12.2M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 11.9M USD +886%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +54.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 88.9M USD +97556%
Lessee, Operating Lease, Liability, to be Paid, Year Three 12.5M USD
Deferred Tax Assets, Operating Loss Carryforwards 50.8M USD +26.4%
Preferred Stock, Shares Issued 0 shares
Deferred Federal Income Tax Expense (Benefit) 187M USD +26.8%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 12.9M USD
Operating Lease, Payments 2.34M USD +511%
Additional Paid in Capital 396M USD +2.7%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 29.7M USD +2387%
Share-based Payment Arrangement, Expense 10M USD +19.5%
Deferred State and Local Income Tax Expense (Benefit) 180M USD +25.4%
Interest Expense 718K USD -71.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%